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AbstractmicroRNAs (miRNAs) are a class of small, non-coding RNAs that regulate the expression of a diverse array of genes and path-ways, with important roles in disease pathogenesis. Many of these miRNAs are currently under investigation as biomarkers or therapeutic options in a range of diseases. Here, we discuss the role of miRNAs in atopic dermatitis, a relapsing chronic pruritic 
inflammatory skin disease of unknown etiology, as they have been strongly implicated in the pathogenesis of skin inflammation. We outline the history and application of miRNAs for the detection and treatment of atopic dermatitis in comparison with other diseases, such as cancer and cardiovascular disease, which may assist the development of diagnostic and therapeutic strategies.
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IntroductionmicroRNAs (miRNA) are a class of small, non-coding RNAs ~21-25 nucleotides in length. Over 1000 human miRNAs have 
been identified to date, primarily located in the intronic re-gions of other genes. These structures represent an important form of post-transcriptional gene regulation by directly inhib-
iting gene translation through their binding of the 3′ untrans-lated regions of their target messenger RNA (mRNA), resulting in lower mRNA stability, or translation inhibition [1,2]. The effects of these miRNAs are far reaching, with more than 30% of the entire genome affected, including critical processes, such as development, differentiation, cell growth, and apop-tosis. This central role of miRNAs in overall cell function has drawn considerable interest from cancer researchers, as can-cers ultimately arise as a result of aberrant gene expression. 
As miRNAs are readily detected in accessible body fluids, such as saliva, blood, urine, and even hair follicles, this suggests the possibility of miRNAs as potential biomarkers of human dis-eases. This review summarizes the molecular mechanisms of miRNA activity, highlights recent studies demonstrating their application as both biomarkers and therapy targets, and ex-plores their therapeutic potential for the treatment of atopic dermatitis (AD).
miRNAs as biomarkers and therapeutic targets in 
cancer and cardiovascular disease
miRNAs were first identified in the mid-1990s with the discov-ery of Let-7 and Lin-4 in the model organism Caenorhabditis 
elegans [3,4]. Homologs have since been identified in nearly 
all eukaryotic organisms, with significant conservation among species. Given the strong conservation of these structures, and their central role in processes such as development, differenti-ation, cell growth, and apoptosis, it was not surprising reports of aberrant miRNAs expressed in cancers and other diseases emerged soon thereafter.Ongoing clinical trials are currently assessing the correlation between miRNA expression and disease prognosis in cancer. As in vitro expression profiles of many tumor-derived miRNAs have shown promise for the diagnosis of patients, miRNA ex-
pression profiles might be used to precisely classify various cancer types, and might be superior to gene expression pro-
files in classification of tumors. More widespread screening before the onset of disease is also possible; stable miRNAs de-
tected in easily accessible fluids, such as serum, plasma, and urine, as well as hair, have shown distinctive patterns of miR-NA expression among patients and controls highlighting their possible use as diagnostic markers [5-7].Interestingly, a single miRNA can simultaneously regulate both tumor suppressive and oncogenic target genes within a single 
cancer [8-11]. For example, miR-196b can target not only the 
HOXA9/MEIS1 oncogenes, but also FAS tumor suppressor gene 
in mixed lineage leukemia-rearranged leukemia [8,9]. This 
implies that tumor initiation and development, as influenced by miRNAs, might be more complex than previously thought, which has important implications for using miRNAs as thera-peutic agents. To date, several drugs have been shown to alter miRNA expression, including the bioactive agent docosahex-aenoic acid, which inhibits the expression of miR-21, a protu-morigenic miRNA [12]. Researchers are currently designing inhibitors for oncogenic miRNAs, along with mimics for tu-mor-suppressor miRNAs, which can act alone or synergistical-ly with currently approved treatments [12,13].
In addition to cancer, many miRNAs have been identified as novel biomarkers and potential therapeutic targets for car-diovascular diseases (CVD). miRNAs play a crucial role in the biogenesis and function of the cardiovascular gene regulato-ry system, and have been implicated as dynamic regulators of 
cardiac and vascular signaling and arterial remodeling [14-16]. For example, in atherosclerosis, miRNA expression is directly 
regulated by blood flow, with endothelial cell miRNA expres-
sion increased in response to laminar or high flow, and other 
decreased in cases of low or disturbed flow [15,16]. Together, this regulatory dynamic suggests a possible therapeutic use of miRNAs as inhibitors of atherosclerosis development. The en-dothelial cell-derived mechano-sensitive miR-143/145 can be delivered to smooth muscle cells via endothelial extracellular vesicles, exerting atheroprotective effects in smooth muscle 
cells [16]. Recent research has also suggested the use of sta-
ble miRNAs circulating in body fluids as potential biomarkers for cardiovascular diseases. The muscle-enriched miR-1, miR-
133 and miR-499-5p, as well as the cardiomyocyte-specific miR-208, have been extensively investigated for their diagnos-tic ability in plasma of patients with coronary artery disease [17,18]. These observations strongly suggest a role for circu-lating miRNAs as a blood-based biomarker for cardiovascular diseases.Several studies have demonstrated the potential therapeutic use of miRNAs to modulate disease processes by antagoniz-ing miRNA expression or increasing their inhibitor functions. 
For example, targeted expression of miR-590 and miR-199a in heart cells using an adeno-associated viral vector demonstrat-ed a re-entry of cardiomyocytes into the cell cycle, resulting in reduced infarct size and improved cardiac function [18].
miRNAs and allergic diseases
Atopic dermatitis (AD) is a chronically relapsing inflamma-tory skin disease that results from a combination of genetic susceptibility and heightened immunologic responses to envi-ronmental allergens. Recently, the role of miRNAs in disease pathogenesis has begun expanding outside of the realms of cancer and CVD to allergic diseases, such as AD, with signif-
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alleviation of airway inflammation in a murine model of asth-ma [27]. Similarly, the miR-200 family of miRNAs regulates ex-pression of E-cadherin, with suppression of E-cadherin is as-sociated with increases in CCL17, a Th2 cell chemoattractant [28]. Other miRNAs, such as miR-1 and miR-155, also play a 
role in allergic inflammation, as suppression of these miRNAs 
by VEGFA contributes to Th2 inflammation in the endothelium and promotes recruitment of activated T cells and subsequent 
eosinophilic inflammation, together with Th2 cytokine pro-
duction [29,30].Recently, our group demonstrated that miRNA targeting CCL22 
suppressed inflammatory responses in macrophages and in an animal model of AD [31,32]. This MDC/CCL22 axis was direct-
ly implicated in Th2-associated skin inflammatory reactions 
with significant increases in serum concentrations strongly correlated with disease severity in AD. In those studies, a recombinant strain of Salmonella typhimuri-
um expressing CCL22 miRNA (ST-miRCCL22) was used for the 
in vivo knockdown of CCL22 as a treatment for AD. ST-miRC-
CL22 was shown to significantly downregulate CCL22 expres-sion in activated lymphocytes in vitro. Subsequent in vivo anal-yses in a mouse model of AD revealed decreases in both IL-4 
and IgE expression, alongside increases in IFNγ; Th17 cells were also suppressed in AD mice treated with ST-miRCCL22. Together, these data suggest that targeted miRNA delivery may be an effective method for the treatment of AD (Figure 1). 
icant attention paid to both genetic and environmental fac-
tors. AD is an inflammatory skin disease that results from a combination of genetic predisposition, imbalanced immune responses, epidermal barrier abnormalities, and severe pru-ritus. A Th1/Th2 imbalance is a key factor in the pathogenesis of allergic diseases such as AD, with some reports implicating miRNA regulation of innate and adaptive immune responses in 
Th2 polarization [19-23]. Immune cells, including monocytes/macrophages, and dendritic cells, as well as T and B lympho-cytes, play a key role in AD [23]. miRNAs have been shown to regulate an array of immune cell functions, including macro-
phage-derived cytokines (MDC) and the expression of inflam-matory mediators in the context of AD [23,24]. miRNA expres-
sion profiling of human skin with psoriasis and atopic eczema revealed differential miRNA expression compared to healthy subjects, with multiple miRNAs differentially expressed in le-sions skin relative to that of healthy controls [25]. Depending on the miRNA involved, these structures can function as sup-pressors or activators of various skin diseases (Table 1).The Th1/Th2 imbalance plays a central role in the clinical expression of allergy and asthma, with Th2 cytokines acting as a driving factor in the pathophysiology of allergic diseases 
[19,22,23]. This balance of immune responses is heavily influ-enced by miRNAs, with serum levels providing insights into 
the pathology of allergic diseases [26]. The let-7 family of miR-NAs has been shown to regulate IL-13 production by human T cells, resulting in reduced IL-13 production in the lungs, and 
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Table 1. Roles of miRNAs in Skin Diseases 
Diseases MiRNA Up- regulated 
Down- 
regulated  Function of MiRNA 
Atopic 
dermatitis 
miR-21 ↑   Inhibition of apoptosis in human T cells 
miR-125b ↑   Suppression of keratinocyte proliferation by targeting FGFR2. 
miR-146a ↑   Suppression of chronic skin inflammation  
miR-155 ↑ Promotion of T helper (Th) cell proliferation through the direct targeting of CTLA4 Suppression of BCL6 in inflammation 
  
  
Psoriasis 
  
  
  
  
  
miR-21 ↑ ↓ Induction of proliferation by targeting PTEN in human keloid fibroblasts 
miR-31 ↑  ↓ Induction of inflammatory cytokine and chemokine production by directly targeting serine/threonine kinase 40 (STK40), a negative regulator of NF-κB signaling   
miR-99   ↓ Wound healing by downregulating the AKT/mTOR signaling 
miR-125b ↑   Suppression of hyper-proliferation and aberrant differentiation of keratinocytes. 
miR-146a ↑   Suppression of innate immune responses in keratinocytes 
miR-203 ↑   Suppression of highly proliferating keratinocytes 
miR-221 ↑   Tissue inhibitor of metalloprotease-3 
miR-424   ↓ Inhibition of keratinocyte proliferation through downregulation of MEK1 or cyclin E1 
ConclusionsmiRNAs have been suggested as potential biomarkers and therapeutic agents for the treatment of human diseases, such as cancer and cardiovascular disease; similar strategies may also be applicable for the treatment of allergic diseases, such as AD, with multiple products currently in development. Al-though the current state of knowledge regarding the expres-sion, regulation, pharmacokinetics, and safety of miRNAs as a therapeutic strategy remain limited, these compounds hold tremendous promise for the treatment of all stages of AD.
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Figure 1. Oral administration of miRNA-CCL22 using Salmonella typhimurium. Upper panel, The recombinant plasmid 
pcDNATM6.2-GW/EmGFP-miR were electroporated into attenuated S. typhimurium. Lower panel, After oral 
administration of ST-miRCCL22, the therapeutic effects of ST-miRCCL22 on atopic dermatitis-like skin in mice were 
assessed. Changes in IL-4, IFN-γ, and IgE levels in serum were measured by ELISA; Th17 cells were enumerated by FACS 
analysis. Samples were collected 7 days after oral inoculation. 
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